Guido Boehmelt is Director of External Innovation in the globally acting Boehringer Ingelheim “Research Beyond Borders” (RBB) division. He received his PhD from the University of Vienna in 1993 following studies in Biology in Regensburg, Heidelberg and at the Research Institute of Molecular Pathology (IMP) in Vienna. His postdoctoral studies led him to the Ontario Cancer Institute/Princess Margaret Hospital and later to the Amgen Research Institute in Toronto, Canada. His main research interests in these years focused on understanding leukemia development and normal hematopoietic differentiation cues. In 1999 he joined the Boehringer Ingelheim Oncology unit in Biberach, Germany as laboratory head, and was Director of Target- and Lead Discovery, Oncology of Boehringer Ingelheim in Vienna from 2004-2013. Since then he led various external collaborations with universities, biotech companies and public-private consortia for Boehringer Ingelheim as Director Research Networking. Since 2016 he is heading RBB Austria in the identification, evaluation and implementation of innovative therapeutic approaches and technologies for Boehringer Ingelheim´s existing and future therapeutic areas.